martes, 14 de noviembre de 2017

Virulence of Japanese Encephalitis Virus Genotypes I and III, Taiwan - Volume 23, Number 11—November 2017 - Emerging Infectious Disease journal - CDC

Virulence of Japanese Encephalitis Virus Genotypes I and III, Taiwan - Volume 23, Number 11—November 2017 - Emerging Infectious Disease journal - CDC

Volume 23, Number 11—November 2017


Virulence of Japanese Encephalitis Virus Genotypes I and III, Taiwan

Yi-Chin Fan1, Jen-Wei Lin1, Shu-Ying Liao, Jo-Mei Chen, Yi-Ying Chen, Hsien-Chung Chiu, Chen-Chang Shih, Chi-Ming Chen, Ruey-Yi Chang, Chwan-Chuen King, Wei-June Chen, Yi-Ting Ko, Chao-Chin Chang, and Shyan-Song ChiouComments to Author 
Author affiliations: National Chung Hsing University, Taichung, Taiwan (Y.-C. Fan, J.-W. Lin, S.-Y. Liao, J.-M. Chen, Y.-Y. Chen, C.-M. Chen, Y.-T. Ko, C.-C. Chang, S.-S. Chiou)National Defense Medical Center, Taipei, Taiwan (H.-C. Chiu); Tri-Service General Hospital (H.-C. Chiu)Taiwan Mennonite Christian Hospital, Hualien, Taiwan (C.-C. Shih)Tungs’ Taichung MetroHarbor Hospital, Taichung (C.-M. Chen)National Dong Hwa University, Hualien (R.-Y. Chang)National Taiwan University, Taipei (C.-C. King)Chang Gung University, Taoyuan, Taiwan (W.-J. Chen)


The virulence of genotype I (GI) Japanese encephalitis virus (JEV) is under debate. We investigated differences in the virulence of GI and GIII JEV by calculating asymptomatic ratios based on serologic studies during GI- and GIII-JEV endemic periods. The results suggested equal virulence of GI and GIII JEV among humans.
Japanese encephalitis virus (JEV), a mosquitoborne flavivirus, causes Japanese encephalitis (JE). This virus has been reported in Southeast Asia and Western Pacific regions since it emerged during the 1870s in Japan (1). JEVs are divided into 5 genotypes on the basis of envelope structural protein genes for phylogenetic reconstruction. JEV genotype III (GIII) has been the most widely distributed in the temperate zone and is most frequently associated with JEV outbreaks in Asia. JEV genotype I (GI) originated in Indonesia and circulated in Thailand and Cambodia during the 1970s (1). Dominance of GIII was replaced by GI during 1992–2001 in Japan, Korea, Thailand, and Vietnam (1).
In Japan, the confirmed case incidence of JEV suddenly decreased from 20–50 cases each year during 1980–1990 to <10 cases after 1992 (2). This decrease may be related to implementation of JEV vaccine in Japan but also to less virulent GI JE viruses circulating there (36). A similar decrease was not seen in the other countries where genotype replacement had also occurred in recent years (7). In Taiwan, JEV GI was first detected in 2008 and became the island-wide dominant circulating genotype within a year (8,9), which provided an excellent opportunity to study the transmission dynamics and pathogenicity of these 2 JEV genotypes.
A mouse model showed that the pathogenic potential is similar among different JEV genotypes (10). However, the pathogenic difference between GI and GIII virus infections among humans remains unclear. Endy et al. reported that the proportion of asymptomatic infected persons among total infected persons (asymptomatic ratio) is an excellent indicator for estimating virulence or pathogenicity of dengue virus infections among humans (11). We used the asymptomatic ratio method for a study to determine if GI JEV is associated with lower virulence than GIII JEV among humans in Taiwan.

The Study

JEVs were identified in 6 locations in Taiwan during 1994–2012 (Technical Appendix[PDF - 306 KB - 3 pages]Figure, panel A). GIII viruses were the only known circulating JEVs in Taiwan before 2009 (Technical Appendix[PDF - 306 KB - 3 pages]Figure, panel B). A genotype shift was complete by 2009, and since then, all JEV isolates in Taiwan have evolved from GI viruses (8). To investigate differences in the virulence of GIII and GI viruses in human infections, we conducted a subcohort and cross-sectional combined study to determine the JEV asymptomatic infection ratio. We used serum panels collected during the GIII JEV endemic period (1994–2000 [12,13]) and during the GI JEV endemic pe-riod (2010–2012).
The institutional review boards of the Mennonite Christian Hospital and the Tungs’ Taichung Metroharbor Hospital reviewed and approved clinical protocols for the serum sample collection. Approximately 10% of total specimens were paired serum samples. We used the plaque reduction neutralization test (PRNT) and IgM antibody-capture ELISA (MAC-ELISA) to determine the infection status of each serum specimen (14). We tested serum panels collected before and after 2009 by using MAC-ELISA and PRNT and used viral antigens and viruses derived from the GIII-T1P1 and GI-YL2009–4 strains, respectively.
We further tested all neutralizing and IgM antibody-positive specimens by using GI YL2009–4, GIII T1P1, and dengue virus 2 (DENV-2) viral antigens to determine the genotype-specific infection status and to exclude false-positive results possibly caused by DENV infection. We used SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) for statistical analyses.
We collected 5,557 specimens from 4,617 participants (Table 1). The average participant age by year ranged from 40.9 to 52.0 years (p<0.05); overall, 49.6% of participants were male and 50.4% female (p>0.05). The proportion of persons receiving JEV vaccinations increased over time from 33% to 49% (p<0.05).
The positivity rate for neutralizing antibody, elicited by natural infection or immunization in the past, differed significantly, ranging from 58% to 75% among the 8 serum panels (p<0.05) (Table 2). A JEV infection that had been acquired recently was indicated by the presence of IgM among the seronegative population, seroconversion of the neutralizing antibody, and a ≥4-fold increase in the neutralizing antibody titer among the seropositive population. For the 8 serum panels, the IgM positivity rate ranged from 0.90% to 4.91% (p<0.05), and the proportion of seroconversion and a ≥4-fold increase in the neutralizing antibody titer ranged from 0% to 1.37% (p>0.05). The incidence rate of JEV infection ranged from 1.83% to 5.49% (p<0.05) in the 8 serum panels.
We calculated the asymptomatic ratio by dividing the number of confirmed JE cases by the number of JEV infection cases. The number of confirmed JE cases (Table 2) was obtained from the CDC National Infectious Disease Statistics System, Taiwan (, which reported 1–4 cases/year in the regions from which the 8 serum panels were collected (Table 2). The number of JEV infection cases, calculated by multiplying the total population by the incidence of JEV infection, ranged from 10,243 to 53,657 in the 8 serum panels. The asymptomatic ratios (95% CI) for GIII virus infection were 1:6,640 (1:5,102–1:8,000) for Changhua County in 1994; 1:17,886 (1:15,408–1:21,322) for Taipei City in 1995; 1:8,779 (1:8,000–1:9,709) for Pingtung County in 1999; and 1:10,243 (1:8,065–1:13,947), for Miaoli County in 2000. The asymptomatic ratios for GI virus infection were 1:7,029 (1:6,329–1:7,874) for Taichung City and 1:6,063 (1:5,348–1:6,993) for Hualien County in 2010; ratios were 1:12,410 (1:10,846–1:14,493) for Taichung City and 1:8,435 (1:7,229–1:10,010) for Hualien County in 2012.
We applied the log-linear Poisson regression model to adjust the asymptomatic ratio by the number of patients who had encephalitis and were infected by other pathogens, and also by age, sex, and vaccination status (Technical Appendix[PDF - 306 KB - 3 pages]Table) (15). The results revealed that non–JEV-specific encephalitis symptoms (fever, headache, convulsion, and seizure) (intercept, p<0.05) influenced the calculation of asymptomatic ratios but not age, sex, or vaccination status (p>0.05).
Thumbnail of JEV genotype-specific asymptomatic ratios. The adjusted asymptomatic ratios estimated from genotype-representing populations were included to calculate JEV genotype-specific asymptomatic ratios. JEV, Japanese encephalitis virus.
Figure. JEV genotype-specific asymptomatic ratios for 8 serum panels collected during the GIII- and GI-endemic periods (1994–2000 and 2010–2012) in Taiwan. The adjusted asymptomatic ratios estimated from genotype-representing populations were included to...
We calculated the overall GI JEV–­ and GIII JEV–specific asymptomatic ratios by using the adjusted asymptomatic ratios of the 8 serum panels collected during the GI JEV– and GIII JEV–endemic periods (Figure). The GI-specific asymptomatic ratio was 1:15,378 (1:6,168–1:24,588) and the GIII-specific ratio was 1:18,842 (1:6,624–1:30,260); these ratios were not significantly different (p>0.05).


The possible effects of JEV genotype replacement remain unclear, particularly in terms of disease burden, virulence, vaccine efficacy, and policy decisions. In this study, we combined the IgM seropositivity rate, the proportion of seroconversion, and paired samples displaying a ≥4-fold increase in the neutralizing antibody titer to calculate incidence of the infection (Table 2). The results showed that the incidence of JEV infection fluctuated over years and in different regions in Taiwan. Nevertheless, genotype replacement had no significant effect on this fluctuation (GI:GIII = 3.78 ± 1.25:2.82 ± 3.18; p>0.05).
The dramatic decline observed in the number of clinical JE cases after the genotype replacement from GIII to GI in Japan suggested that GI viruses were less virulent than GIII viruses (36). However, we found that the asymptomatic ratio of GI and GIII JEV infections was similar, indicating equal virulence of GIII and GI JEVs. These results were also supported by the mouse virulence and neurovirulence experiments and disease burden estimation (10).
Dr. Fan is a postdoctoral researcher at Graduate Institute of Microbiology and Public Health, National Chung Hsing University, Taiwan. Her research interests focus on the host tropism of flavivirus and the underlying mechanism(s) of genotype replacement of Japanese encephalitis virus.


We thank the study subjects and the nurses of the Mennonite Christian Hospital and the Tungs’ Taichung MetroHarbor Hospital for their assistance with the study subjects and specimen processing.
This work was supported by the Ministry of Science and Technology, R.O.C. (research grant NSC 102-2321-B-005-019).


  1. Pan XLLiu HWang HYFu SHLiu HZZhang HLet al. Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol2011;85:984753DOIPubMed
  2. Arai SMatsunaga YTakasaki TTanaka-Taya KTaniguchi KOkabe Net al.Vaccine Preventable Diseases Surveillance Program of JapanJapanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis2008;61:3338.PubMed
  3. Nerome RTajima STakasaki TYoshida TKotaki ALim CKet al. Molecular epidemiological analyses of Japanese encephalitis virus isolates from swine in Japan from 2002 to 2004. J Gen Virol2007;88:27628DOIPubMed
  4. Takegami TIshak HMiyamoto CShirai YKamimura KIsolation and molecular comparison of Japanese encephalitis virus in Ishikawa, Japan. Jpn J Infect Dis2000;53:1789.PubMed
  5. Han NAdams JChen PGuo ZYZhong XFFang Wet al. Comparison of genotypes I and III in Japanese encephalitis virus reveals distinct differences in their genetic and host diversity. J Virol2014;88:1146979DOIPubMed
  6. Konishi EKitai YTabei YNishimura KHarada SNatural Japanese encephalitis virus infection among humans in west and east Japan shows the need to continue a vaccination program. Vaccine2010;28:266470DOIPubMed
  7. Han NAdams JFang WLiu SQRayner SInvestigation of the genotype III to genotype I shift in Japanese encephalitis virus and the impact on human cases. Virol Sin2015;30:27789DOIPubMed
  8. Chen YYFan YCTu WCChang RYShih CCLu IHet al. Japanese encephalitis virus genotype replacement, Taiwan, 2009-2010. Emerg Infect Dis2011;17:23546DOIPubMed
  9. Huang JHLin THTeng HJSu CLTsai KHLu LCet al. Molecular epidemiology of Japanese encephalitis virus, Taiwan. Emerg Infect Dis2010;16:8768DOIPubMed
  10. Beasley DWLi LSuderman MTGuirakhoo FTrent DWMonath TPet al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine2004;22:37226DOIPubMed
  11. Endy TPAnderson KBNisalak AYoon IKGreen SRothman ALet al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis2011;5:e975DOIPubMed
  12. Chiou SS, King CC. Japanese encephalitis virus recent infection: detection of IgM antibody. Report of undergraduate student research grant, National Science Council, Taiwan. 1994
  13. Chiou SSTsai KHHuang CGLiao YKChen WJHigh antibody prevalence in an unconventional ecosystem is related to circulation of a low-virulent strain of Japanese encephalitis virus. Vaccine2007;25:143743.
  14. Chiou SSCrill WDChen LKChang GJEnzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol2008;15:82535DOIPubMed
  15. Wang TELin CYKing CCLee WCEstimating pathogen-specific asymptomatic ratios. Epidemiology2010;21:7268DOIPubMed



Technical Appendix

Cite This Article

DOI: 10.3201/eid2311.161443
1These authors contributed equally to this article.

No hay comentarios:

Publicar un comentario